TCT Conference 2024 - Routine use of orbital atherectomy system (OAS) did not improve minimal stent area (MSA) or target vessel failure (TVF) at one year compaared to conventional balloon angioplasty.

Dr Ajay J Kirtane (Columbia University Medical Center and New York-Presbyterian Hospital, New York, US) joins us onsite at TCT Conference to discuss the findings from ECLIPSE (NCT03108456; Abbott Medical Devices).

ECLIPSE is a prospective, multicenter trial, where patients with severe calcified coronary artery lesions were randomised to receive either the Diamondback 360 OAS (Abbott Medical Devices) or conventional balloon angioplasty. 2005 patients were enrolled in the trial and followed-up at one and two years. The primary outcome measures were the assessment of the in-stent minimal cross-sectional area and target vessel failure.

ECLIPSE did not meet its primary outcome measures, where OAS did not improve MSA and TVF when compared to conventional balloon angioplasty for the preparation of severely calcified lesions prior to drug eluting stent implantation. Adequate stent expansion and low rates of adverse outcomes were found to be achievable with conventional balloon angioplasty in a large proportion of calcified lesions, if close attention is paid to lesion preparation.

Interview Questions:
1.    What are the current unmet needs in percutaneous coronary intervention, and why is the ECLIPSE trial important?
2.    What was the study design and patient population?
3.    What were the key findings?
4.    What are the take-home messages for clinical practice?
5.    What further research is needed in this area?

Recorded on-site at TCT Conference in Washington, 2024.

Editors: Yazmin Sadik, Jordan Rance
Videographers: David Ben-Harosh, Oliver Miles

Support: This is an independent interview produced by Radcliffe Cardiology.